CA2906581C - A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors, and thiazole intermediates - Google Patents

A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors, and thiazole intermediates Download PDF

Info

Publication number
CA2906581C
CA2906581C CA2906581A CA2906581A CA2906581C CA 2906581 C CA2906581 C CA 2906581C CA 2906581 A CA2906581 A CA 2906581A CA 2906581 A CA2906581 A CA 2906581A CA 2906581 C CA2906581 C CA 2906581C
Authority
CA
Canada
Prior art keywords
formula
compound
halo
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2906581A
Other languages
English (en)
French (fr)
Other versions
CA2906581A1 (en
Inventor
Craig Siegel
Rayomand GIMI
Michael Reardon
Jin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CA3092901A priority Critical patent/CA3092901C/en
Publication of CA2906581A1 publication Critical patent/CA2906581A1/en
Application granted granted Critical
Publication of CA2906581C publication Critical patent/CA2906581C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2906581A 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors, and thiazole intermediates Active CA2906581C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3092901A CA3092901C (en) 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791913P 2013-03-15 2013-03-15
US61/791,913 2013-03-15
PCT/US2014/025384 WO2014151291A1 (en) 2013-03-15 2014-03-13 Method of preparing glucosylceramide synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3092901A Division CA3092901C (en) 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors

Publications (2)

Publication Number Publication Date
CA2906581A1 CA2906581A1 (en) 2014-09-25
CA2906581C true CA2906581C (en) 2022-09-20

Family

ID=50543333

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2906581A Active CA2906581C (en) 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors, and thiazole intermediates
CA3092901A Active CA3092901C (en) 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3092901A Active CA3092901C (en) 2013-03-15 2014-03-13 A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors

Country Status (20)

Country Link
US (4) US9682975B2 (https=)
EP (2) EP2970251B1 (https=)
JP (2) JP6543242B2 (https=)
KR (1) KR20150130386A (https=)
CN (2) CN105189491B (https=)
AR (1) AR095436A1 (https=)
AU (2) AU2014235132B2 (https=)
BR (1) BR112015020667A2 (https=)
CA (2) CA2906581C (https=)
CY (1) CY1121859T1 (https=)
DK (1) DK3514157T3 (https=)
ES (2) ES2968073T3 (https=)
HU (2) HUE043394T2 (https=)
IL (2) IL240617B (https=)
MX (2) MX365464B (https=)
RU (1) RU2015144035A (https=)
SG (2) SG10201706575UA (https=)
TW (2) TWI649317B (https=)
UY (1) UY35438A (https=)
WO (1) WO2014151291A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TWI649317B (zh) 2013-03-15 2019-02-01 健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法
EP3583653B1 (de) * 2017-02-17 2020-12-16 Westfälische Wilhelms-Universität Münster Elektrolyt-zusatz für lithium-ionen-batterien
JP2021506920A (ja) 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
JP7725076B2 (ja) 2020-04-28 2025-08-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725226A (en) * 1952-06-03 1955-03-02 Berger Brothers Co Improvements in or relating to an inflatable surgical pad
GB725228A (en) * 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
NL130759C (https=) * 1965-10-07
DE4326510A1 (de) 1993-08-06 1995-02-09 Bayer Ag Verfahren zur Herstellung von Cyclohexen-Derivaten
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
JP5285643B2 (ja) * 2010-03-15 2013-09-11 シャープ株式会社 半導体集積回路および電子情報機器
RU2607084C2 (ru) 2010-11-12 2017-01-10 Сионоги Энд Ко., Лтд. Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения
AU2012231275A1 (en) * 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
JP2013053228A (ja) * 2011-09-02 2013-03-21 Asahi Kasei E-Materials Corp エポキシ樹脂用硬化剤及びマイクロカプセル型エポキシ樹脂用硬化剤
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TWI649317B (zh) * 2013-03-15 2019-02-01 健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法

Also Published As

Publication number Publication date
US20160039806A1 (en) 2016-02-11
AU2014235132B2 (en) 2018-08-02
EP3514157A1 (en) 2019-07-24
US9682975B2 (en) 2017-06-20
CN105189491B (zh) 2018-07-06
EP3514157B1 (en) 2023-09-06
DK3514157T3 (da) 2023-11-27
JP6813626B2 (ja) 2021-01-13
SG10201706575UA (en) 2017-09-28
CA2906581A1 (en) 2014-09-25
EP2970251A1 (en) 2016-01-20
US20190031652A1 (en) 2019-01-31
HK1220689A1 (en) 2017-05-12
US20200181137A1 (en) 2020-06-11
TW201900625A (zh) 2019-01-01
KR20150130386A (ko) 2015-11-23
HUE043394T2 (hu) 2019-08-28
MX365464B (es) 2019-06-04
WO2014151291A1 (en) 2014-09-25
UY35438A (es) 2014-10-31
IL240617A0 (en) 2015-10-29
RU2015144035A (ru) 2017-04-20
EP2970251B1 (en) 2019-02-27
US20170334903A1 (en) 2017-11-23
TWI649317B (zh) 2019-02-01
AU2014235132A1 (en) 2015-09-24
JP2016512838A (ja) 2016-05-09
JP2019167379A (ja) 2019-10-03
US10065949B2 (en) 2018-09-04
US10604518B2 (en) 2020-03-31
IL259770B (en) 2020-04-30
CY1121859T1 (el) 2020-07-31
ES2968073T3 (es) 2024-05-07
CA3092901C (en) 2024-01-02
CA3092901A1 (en) 2014-09-25
JP6543242B2 (ja) 2019-07-10
AR095436A1 (es) 2015-10-14
HUE064200T2 (hu) 2024-02-28
IL240617B (en) 2019-08-29
CN108658970A (zh) 2018-10-16
AU2019200350A1 (en) 2019-02-07
US10954230B2 (en) 2021-03-23
BR112015020667A2 (pt) 2017-07-18
ES2727869T3 (es) 2019-10-21
IL259770A (en) 2018-07-31
RU2015144035A3 (https=) 2018-03-01
MX389168B (es) 2025-03-20
TW201524974A (zh) 2015-07-01
SG11201506415XA (en) 2015-09-29
CN105189491A (zh) 2015-12-23
MX2015012842A (es) 2016-02-03

Similar Documents

Publication Publication Date Title
CA2906581C (en) A method of preparing glucosylceramide synthase quinuclidine carbamate inhibitors, and thiazole intermediates
JP6994496B2 (ja) 芳香族アセチレンまたは芳香族エチレン系化合物、その中間体、製造方法、薬物組成物および使用
KR20110117215A (ko) ５-원 헤테로시클릭 화합물의 아자스피라닐-알킬카르바메이트의 유도체, 그의 제조법, 및 그의 치료 용도
KR102029516B1 (ko) 아자 아다만탄의 유도체 및 이의 용도
HK40012168A (en) Method of preparing glucosylceramide synthase inhibitors
HK40012168B (en) Method of preparing glucosylceramide synthase inhibitors
AU2017258665A1 (en) Process for the preparation of herbicidal compounds
HK1220689B (en) Method of preparing glucosylceramide synthase inhibitors
JP2000229978A (ja) オキサゾリジノン及び抗菌剤としてのそれらの使用
KR100467309B1 (ko) 옥사졸리디논유도체및그의제조방법및항균제조성물
HK1181384A1 (en) Method for producing substituted pyridin-2-one
HK1181384B (en) Method for producing substituted pyridin-2-one
CA2575417A1 (en) Chiral pyrrolidine derivatives, and methods for preparing compounds thereof
CA2751866A1 (fr) Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260312

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260312